Cagrilintide vs Tesamorelin
Extensively Studied vs FDA Approved
synergistic Mechanism-based · 60% Cagrilintide helps counteract the insulin-disrupting effects of Tesamorelin. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Cagrilintide Tesamorelin
Weight 4,409.01 Da 5,135.9 Da
Half-life ~7 days (159-195 hours) 26-38 minutes
Chain 37 amino acids 44 amino acids
Type Amylin receptor agonist GHRH analog
Key Benefits
Cagrilintide
01 FDA development candidate with extensive Phase 3 data
02 Superior weight loss in combination with semaglutide (22.7%)
03 Once-weekly convenience
04 2.2% HbA1c reduction with CagriSema
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
Cagrilintide
2.4mg weekly (after escalation) / Once weekly, same day each week
Weight Loss (Monotherapy) 2.4mg Once weekly
Weight Loss (CagriSema) 2.4mg + semaglutide 2.4mg Once weekly
Type 2 Diabetes Management 2.4mg weekly Once weekly
Dose Escalation Protocol 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg Weekly increases over 16 weeks
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
Cagrilintide
Gastrointestinal effects (nausea, vomiting, diarrhea) during initial weeks
Anti-cagrilintide antibodies develop in 46-73% but do not affect efficacy
Only 57.3% achieved maximum 2.4mg dose in REDEFINE 1 trial
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Not recommended in pregnancy or breastfeeding
Not yet commercially available (FDA approval expected Q1 2026)
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
Cagrilintide Tesamorelin
Status Extensively Studied FDA Approved
References 3 studies 5 studies
Latest December 2025 June 2025
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.